OncoImmune Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$678M
OncoImmune General Information
Description
Operator of a clinical-stage biopharmaceutical company engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. The company's offerings include recombinant fusion protein that targets a novel immune pathway checkpoint, enabling doctors to help treat diseases targeting the immune system.
Contact Information
Website
www.oncoimmune.comCorporate Office
- 9430 Key West Avenue
- Suite 113
- Rockville, MD 20850
- United States
Corporate Office
- 9430 Key West Avenue
- Suite 113
- Rockville, MD 20850
- United States
OncoImmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 01-Dec-2020 | $678M | Completed | Clinical Trials - Phase 3 | ||
| 7. Later Stage VC (Series B) | 09-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series A1) | 22-May-2020 | Completed | Clinical Trials - Phase 3 | |||
| 5. Grant | 01-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 01-Jan-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A) | 12-Jan-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 01-Jan-2017 | $2M | Completed | Clinical Trials - Phase 2 | ||
| 1. Early Stage VC | 01-Jan-2004 | Completed | Startup |
OncoImmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 2,601,833 | $0.000100 | $3.84 | $3.84 | 1x | $3.84 | 4.52% |
OncoImmune Comparisons
Industry
Financing
Details
OncoImmune Competitors (2)
One of OncoImmune’s 2 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
OncoImmune Patents
OncoImmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230103352-A1 | Methods of use of soluble cd24 for treating sars-cov-2 infection | Inactive | 24-Sep-2020 | ||
| US-20230108492-A1 | Methods of use of soluble cd24 for treating viral pneumonia | Inactive | 09-Apr-2020 | ||
| EP-4103218-A1 | Methods of use of soluble cd24 for treating sars-cov-2 infection | Inactive | 10-Feb-2020 | ||
| EP-4103218-A4 | Methods of use of soluble cd24 for treating sars-cov-2 infection | Inactive | 10-Feb-2020 | ||
| WO-2021160170-A1 | Methods of use of soluble cd24 for treating sars-cov-2 infection | Inactive | 10-Feb-2020 | A61K38/177 |
OncoImmune Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Falcon Creek Capital | Venture Capital | Minority | ||
| GBA Capital | PE/Buyout | Minority | ||
| GF Xinde Investment Management | PE/Buyout | Minority | ||
| HM Capital | Venture Capital | Minority |
OncoImmune FAQs
-
When was OncoImmune founded?
OncoImmune was founded in 2000.
-
Where is OncoImmune headquartered?
OncoImmune is headquartered in Rockville, MD.
-
What industry is OncoImmune in?
OncoImmune’s primary industry is Drug Discovery.
-
Is OncoImmune a private or public company?
OncoImmune is a Private company.
-
What is the current valuation of OncoImmune?
The current valuation of OncoImmune is .
-
What is OncoImmune’s current revenue?
The current revenue for OncoImmune is .
-
How much funding has OncoImmune raised over time?
OncoImmune has raised $74M.
-
Who are OncoImmune’s investors?
3E Bioventures (China), Falcon Creek Capital, GBA Capital, GF Xinde Investment Management, and HM Capital are 5 of 12 investors who have invested in OncoImmune.
-
Who are OncoImmune’s competitors?
Sorrento Therapeutics and Genetix Biotherapeutics are competitors of OncoImmune.
-
When was OncoImmune acquired?
OncoImmune was acquired on 01-Dec-2020.
-
Who acquired OncoImmune?
OncoImmune was acquired by Merck & Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process